Celltrion, Inc. (068270.KS)
| Previous Close | 194,400.00 |
| Open | 195,400.00 |
| Bid | 194,500.00 x 0 |
| Ask | 194,600.00 x 0 |
| Day's Range | 193,500.00 - 196,300.00 |
| 52 Week Range | 131,000.00 - 241,000.00 |
| Volume | |
| Avg. Volume | 646,576 |
| Market Cap | 40.253T |
| Beta (5Y Monthly) | 0.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 500.00 (0.26%) |
| Ex-Dividend Date | Dec 27, 2023 |
| 1y Target Est | N/A |
- PR Newswire
Celltrion USA signs agreement with Express Scripts for its therapy for autoimmune diseases including the first FDA-approved subcutaneous infliximab ZYMFENTRA™
Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people. The agreement, effective April 4, 2024 provides ZYMFENTRA Preferred Brand Access on the Express Scripts National Preferred Formulary serving 21.9 Million insured lives. Express Scripts provides plan participants such as Health Plans of the PBM the ability to add ZYMFENTRA™ (inf
- PR Newswire
ZYMFENTRA™(infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab, now commercially available in the U.S.
Celltrion USA announced today the availability of a ZYMFENTRA™ (infliximab-dyyb), a subcutaneous (SC) formulation of infliximab.[1] ZYMFENTRA is the first and only subcutaneous infliximab approved by the U.S. Food and Drug Administration (FDA) in 2023.
- PR Newswire
Celltrion USA completes submission of Biologics License Application (BLA) to U.S. FDA for CT-P39, an interchangeable biosimilar candidate of XOLAIR® (omalizumab)
Celltrion USA today announced that the company has submitted a Biologics License Application (BLA) for CT-P39, an interchangeable biosimilar candidate to XOLAIR® (omalizumab) to the U.S. Food and Drug Administration (FDA).[1]
